Amana Developing World ETFAMEM

Amana Developing World ETF (AMEM) is a thinly traded wrapper around the Amana Developing World Index, a 150-stock basket tilted toward Asia and Africa, screened for ‘faith-based’ exclusions. The fund’s 0.65% expense ratio and 0.25% 12b-1 fee quietly siphon 90 basis points per year from any return an investor might hope to capture. The Nasdaq listing confirms daily volume is modest, leaving it vulnerable to price swings from even modest order flow. The issuer’s SEC filings and FINRA Fund Analyzer entries confirm the replication strategy, but nothing in the evidence supports relative strength versus a DIY portfolio built from the same index constituents.

The fund’s mandate is straightforward: exclude alcohol, tobacco, and weapons, then charge a fee for the privilege of owning the remainder. The marketing calls it an ‘ethical mandate,’ but the evidence shows it’s still just a fee extraction mechanism wrapped in a noble-sounding label. The fund’s net assets are below $50 million, a figure that sits somewhere between ‘boutique experiment’ and ‘rounding error’ depending on whether you’re the issuer’s finance team or a retail buyer. The Nasdaq page lists the fund’s ticker, but the real story is the gap between the glossy pitch and the thin liquidity and high fees buried in the filings.

The SEC EDGAR filings for AMEM confirm the fund’s replication approach and fee structure, while the FINRA Fund Analyzer spells out the 12b-1 charge at 0.25%. There’s no evidence in the supplied sources of relative strength, alpha, or any structural advantage over a self-built portfolio using the same index constituents and a discount brokerage account. The issuer’s marketing materials frame the fund as a ‘frontier markets growth engine,’ but the evidence shows it’s closer to ‘frontier minus the frontier, plus a 90-basis-point toll.’

The fund’s chart route, if accessed via Nasdaq’s interface, shows price action that is more a reflection of thin liquidity than of any fundamental shift in the underlying basket. The evidence does not support claims of superior risk-adjusted returns, and the fund’s modest assets under management mean it lacks the firepower to negotiate lower fees with index providers or brokers. The tracking error, while not quantified in the supplied sources, is a known risk for small, niche ETFs that rely on replication rather than optimisation.

What changed today: the Nasdaq page for AMEM shows the ticker still exists, with no new filings, earnings, or material developments reported in the supplied sources. The fund’s structure, fees, and mandate remain unchanged from the last filing cycle. The evidence does not include any material corporate actions, index rebalances, or issuer communications that would alter the fund’s risk profile or return expectations. The fund’s liquidity and tracking accuracy remain the primary operational risks, while the issuer’s fee structure remains the primary drag on any potential relative strength.

What remains unproven: whether the fund’s ‘ethical mandate’ delivers any measurable relative strength or risk reduction versus a broad emerging-markets ETF with lower fees; whether the fund’s replication strategy relative strength an optimised sampling approach; and whether the fund’s modest size and liquidity can support a viable long-term track record. The evidence also does not address the fund’s dividend yield, capital gains distributions, or tax efficiency, all of which are material to investors but absent from the supplied sources.